4.7 Article

Arrhythmia-Induced Cardiomyopathies Mechanisms, Recognition, and Management

期刊

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 66, 期 15, 页码 1714-1728

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2015.08.038

关键词

atrial fibrillation; atrial flutter; catheter ablation; heart failure; heart rate; tachycardia

资金

  1. National Institutes of Health (NIH) [HL057952, HL059165, HL095608]
  2. Veterans Affairs Health Administration
  3. Biosense Webster
  4. Boston Scientific
  5. St. Jude Medical
  6. Medtronic
  7. NIH [HL057952, HL059165, HL095608]

向作者/读者索取更多资源

Arrhythmia-induced cardiomyopathy (AIC) is a potentially reversible condition in which left ventricular dysfunction is induced or mediated by atrial or ventricular arrhythmias. Cellular and extracellular changes in response to the culprit arrhythmia have been identified, but specific pathophysiological mechanisms remain unclear. Early recognition of AIC and prompt treatment of the culprit arrhythmia using pharmacological or ablative techniques result in symptom resolution and recovery of ventricular function. Although cardiomyopathy in response to an arrhythmia may take months to years to develop, recurrent arrhythmia can result in rapid decline in ventricular function with development of heart failure, suggesting residual ultrastructural abnormalities. Reports of sudden death in patients with normalized left ventricular ejection fraction cast doubt on the complete reversibility of this condition. Several aspects of AIC, including specific pathophysiological mechanisms, predisposing factors, optimal therapeutic strategies to prevent ultrastructural changes, and long-term risk of sudden death remain unresolved and need further research. (C) 2015 by the American College of Cardiology Foundation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据